incretin peptide that augments glucose-stimulated insulin release following oral consumption of nutrients. Its message is transmitted via a G protein-coupled receptor called GLP-1R, which is colocalized with pancreatic β-cells. The GLP-1 system is responsible for enhancing insulin release, inhibiting glucagon production, inhibiting hepatic gluconeogenesis, inhibiting gastric mobility, and suppression of appetite. The abundance of GLP-1R in pancreatic β-cells in insulinoma, a cancer of the pancreas, and the activity of GLP-1 in the cardiovascular system have made GLP-1R a target for molecular imaging. Methods We prepared 18 
Introduction
The glucagon-like peptide type-1 (GLP-1) is released in the gut following ingestion of nutrients. The peptide is responsible for the stimulation of insulin release from the β-cells of the pancreas to maintain glucose homeostasis. GLP-1 is an incretin that augments the glucose-dependent secretion of insulin, inhibits glucagon production, inhibits hepatic gluconeogenesis, inhibits gastric mobility, and suppresses appetite [1, 2] . Because of this stimulation of insulin release, it is not surprising to find that the target receptor for GLP-1 (GLP-1R) is highly expressed in pancreatic β-cells [3] . GLP-1 must, of necessity, be controlled in its actions to prevent development of hypoglycemia as the blood glucose concentration is reduced by the actions of insulin. Consequently, the native peptide is rapidly degraded by dipeptidyl-peptidase-IV via cleavage of two N-terminal residues, which abolishes the agonistic effects at GLP-1R [4] .
Diabetes is a serious and increasingly common medical condition in which the blood glucose levels are abnormal. Type 1 diabetes is characterized by lack of insulin production in the pancreas, and type 2 diabetes is characterized by high blood glucose concentrations that are often resistant to insulin concentration. Type 2 diabetes is accompanied by a loss of the efficiency of the GLP-1R/GLP-1 system. Secretion of GLP-1 is reduced and the potency of GLP-1 at its receptor is also reduced [1] . GLP-1 agonists and inhibitors of dipeptidyl-peptidase-IV, which prolong the biological half-life of GLP-1, are used in the treatment of type 2 diabetes. Because of the high prevalence of diabetes in the human population, there is keen interest in developing radioactive imaging agents that can be applied to study of the causes and treatment of this disease [5, 6] .
GLP-1R has been shown to be expressed in high density and high incidence in certain types of cancers derived from endocrine, neuroendocrine, and embryonic origins [7] . Benign insulinoma is a neuroendocrine cancer of pancreatic β-cells that displays high levels of both GLP-1R and somatostatin receptors [7] . It is a rare form of cancer, and its lesions are difficult to detect by standard clinical imaging methods due to their small size and the anatomical location in the pancreas. The INS-1 (832/13) cell line is a rat insulinoma cell line with positive GLP-1R expression [8] . The fact that GLP-1R is one of the target receptors for diabetes imaging makes the INS-1 tumor an excellent tissue model to study novel ligands.
Exendin-4 is a subcutaneously administered peptide drug that is used in the treatment of type 2 diabetes. Originally discovered in the saliva of a lizard [9] , exendin-4 was the first of a class of incretin mimetics that showed potent glucoregulatory activity. Research groups have explored GLP-1 imaging with analogs of exendin that have been designed to complex radiometals such as 111 In and 99m Tc for single-photon emission computed tomography (SPECT) and 68 Ga for PET [10] [11] [12] . 123 I-GLP-1(7-36) amide and 123 I-exendin-3 have been studied in a subcutaneous insulinoma model [13] . Images of insulinoma xenografts were obtained with these 123 I-labeled peptides, but both compounds exhibited rapid washout. Wild et al. [10] prepared an 111 In-DTPA-exendin-4 analog, and successfully imaged small insulinomas in the Rip1Tag2 mouse model. This radiotracer demonstrated therapeutic potential at higher doses [14] . This same compound has been utilized clinically to image insulinomas using SPECT [15, 16] . 68 Ga-and 99m Tc-labeled exendin-4 analogs have also been evaluated [11] . One application for these imaging agents is the study of pancreatic β-cell mass during both the course of diabetes development and monitoring of islet transplantation. The GLP-1 receptor radioligand, [Lys 40 (Ahx-DTPA-111 In)NH 2 ]exendin-4, provided imaging of functional β-cells 1 year following islet transplantation into the forearm of a human patient [17] .
We have previously prepared [
18 F]FBEM-EM3106B as a PET imaging agent and evaluated it in the INS-1 xenograft model [18] . EM-3106B was developed to enhance the biological half-life of this class of molecules by inclusion of two cyclic lactam bridges in the structure of the peptide [19] . We extended our previous work by preparing 18 F-labeled analogs of exendin-4. Exendin-4, which contains no cysteine residue in the native structure, was modified with either a C-terminal or N-terminal cysteine to allow site-specific labeling with [ ] analog is [His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-AspLeu-Ser-Lys-Gly-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-PheIle-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-AlaPro-Pro-Pro-Ser-Cys-NH 2 ] and for the [Cys 0 ] analog is [Cys-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-LysGly-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-TrpLeu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH 2 ]. N-[2-(4-Fluorobenzamido)ethyl]maleimide (FBEM) was prepared as previously described [20] . [ 18 F]FBEM was synthesized using an automated system as previously described [21] . For semipreparative HPLC, a Vydac C-18 protein column (9.4 × 250 mm) and a gradient elution profile were used with 0.1% trifluoroacetic acid (TFA) in water (solvent A) and 0.1% TFA in CH 3 CN (solvent B). For analytical HPLC, a Vydac C-18 protein column (4.6 × 250 mm) was used with a gradient elution profile using water, CH 3 CN, 1 mM EDTA Na 2 , and 1% TFA in water (solvent C). For HPLC mass spectrometry, a Waters QTOF coupled to a Waters Acquity UPLC and gradient profile were used with formic acid buffers. ]-Exendin-4 (100-200 μg) in 100 μl 0.1% sodium ascorbate in PBS (ultrasonically degassed) was added, and the solution was vortexed followed by incubation for 30 min. Aqueous TFA (0.1% TFA, 100 μl) was added and the solution injected onto a semipreparative HPLC system. The major radioactivity peak was collected as product. The elution time of the radioactive product was about 17.9 min. The radioactive oxidation product eluted at about 15 ]-exendin-4 was diluted to 20 ml with water and the solution passed through a C-18 BondElut cartridge (100 mg). The product that remained on the cartridge was eluted with 1 ml of 10 mM HCl in ethanol. The ethanol was concentrated on a rotary evaporator to about 100-200 μl. A portion of this remaining volume was used for determination of radiochemical purity and specific activity. The remaining volume was diluted in PBS for in vitro and in vivo studies.
Quality control
For analytical HPLC the column described in general methods was used. The gradient used was 65% water, 25% CH 3 CN, 10% solvent C for 5 min, then a linear gradient to 35% water, 55% CH 3 CN, 10% solvent C by 25 min, and finally, a linear gradient to 90% CH 3 Plasma and serum stability
]-exendin-4 was mixed with 200 μl of human plasma or mouse serum and a 50-μl aliquot was removed at 0 min. The remainder was incubated at 37°C and additional aliquots of 50 μl were removed at 30 and 60 min. The aliquots were mixed with an equal volume of CH 3 CN, the layers were assayed to determine extraction efficiency, and a portion of the supernatant was subjected to radioHPLC analysis using an on-line radioactivity detector or collection of 1-min fractions and counting in a γ-counter (Wallach Wizard, PerkinElmer).
Cell culture and animal model
All animal studies were conducted in accordance with the principles and procedures outlined in the Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the Clinical Center, NIH. The rat insulinoma INS-1-derived 832/13 cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, and 100 μg/ml streptomycin (Invitrogen), and in a humidified atmosphere containing 5% CO 2 at 37°C. The MDA-MB-435 cell line [22] was purchased from the American Type Culture Collection (ATCC) and grown in Leibovitz's L-15 medium supplemented with 10% (v/v) fetal bovine serum under an atmosphere of 100% air at 37°C. The INS-1 and MDA-MB-435 xenograft tumor models were developed in 5-to 6-week old female athymic nude mice (Harlan Laboratories) by injection of 5×10 6 cells into the left or right shoulder. Tumor growth was monitored by measuring perpendicular axes of the tumor using a caliper. The tumor volume was estimated from the formula: tumor volume=a×(b 2 )/2, where a and b are the tumor length and width, respectively, in millimeters. The mice underwent a small-animal PET scan when the tumor volume reached 100-300 mm 3 (3-4 weeks after inoculation).
Cell binding assay
In ]-exendin-4 into INS-1 tumor-bearing mice and 5-min static PET images were acquired at the 1-h time point (four animals). The images were reconstructed using a two-dimensional ordered-subsets expectation maximization (2-D OSEM) algorithm without correction for attenuation or scattering. For each scan, regions of interest (ROIs) were drawn over the tumor and major organs using vendor software (ASI Pro 5.2.4.0) on decay-corrected wholebody coronal images. The radioactivity concentrations (accumulation) within the tumors, muscle, liver, and kidneys were obtained from mean pixel values within the multiple ROI volume and then converted to megabecquerels per milliliter per minute using the calibration factor determined for the Inveon PET system. These values were then divided by the administered activity to obtain (assuming a tissue density of 1 g/ml) an image ROI-derived percent injected dose per gram (%ID/g).
Ex vivo biodistribution
Immediately after PET imaging, the tumor-bearing mice were killed and dissected. Blood, tumor, major organs, and tissues were collected and wet-weighed. The radioactivity in the wet whole tissue was measured with a γ-counter. The results were expressed as percentages of the injected dose per gram of tissue (%ID/g) for a group of six animals. For each mouse, the radioactivity of the tissue samples was calibrated against a known aliquot of the injected radiotracer. were separated on 12% polyacrylamide gels using SDS-PAGE and transferred to nitrocellulose membranes [23] , which were blocked for 1 h at room temperature with TBS containing 5% bovine serum albumin. The blots were washed with TBS containing 0.1% Tween 20 and then incubated with rabbit anti-rat polyclonal GLP-1R antibody (1:500, Abcam). In all determinations, monoclonal antibody for rat β-actin (1:2,000, Abcam) was used as an internal control. After extensive washing, the antigenantibody complexes were detected using horseradish peroxidase-labeled donkey anti-rabbit IgG and a SuperSignal West Pico chemiluminescence kit detection system (Pierce, Rockford, IL).
Statistical analysis
Quantitative data are expressed as means±SD. Means were compared using one-way analysis of variance and Student's t-test. A p value of <0.05 was considered statistically significant.
Results

Syntheses
The chemical and radiochemical syntheses provided adequate amounts of the desired chemical entities. 40 ]-exendin-4. Extraction efficiencies from human plasma were 91%, 72%, and 68% at 0, 30, and 60 min, respectively. In human plasma, only a minor amount of radiolabeled oxidation product was observed in the samples. Parent radiolabeled peptide comprised 92%, 89%, and 88% of the radioactivity at 0, 30, and 60 min, respectively. Mouse serum extraction efficiencies were 87%, 85%, and 82% at 0, 30, and 60 min, respectively. Only a trace amount of a very polar radioactive component was observed that increased slightly over time in the serum incubation. At 60 min, 88% of the radioactivity was collected in the parent product peak. Radioactivity recovery based on gamma counting of collected fractions was 94% for the mouse sample at 60 min, 98% for the human sample at 0 min, and 90% for the human sample at 60 min (Fig. 2) .
Cell uptake and clearance Cellular uptake in vitro was modest with the majority of the radioactivity internalized. FBEM- [Cys 40 ]-exendin-4 showed slightly higher cellular uptake than the [Cys 0 ] isomer. The proportion internalized was not different between the two isomers. Cellular uptake was inhibited with a blocking concentration. The efflux appeared biphasic with an early rapid phase, probably reflecting loss of surface binding, followed by a slow phase representing clearance of the intracellular pool (Fig. 3) . The [Cys 0 ] isomer exhibited faster and more extensive efflux.
Xenograft imaging and biodistribution studies
We utilized the INS-1 tumor as a GLP-1 receptor-positive tumor and MDA-MB-435 tumor as a negative control. Western blotting showed the relative amounts of GLP-1 in the two tumor types (Fig. 4) ]-exendin-4 (0.79±0.080 %ID/g at 1 h). The highest uptake was observed at the earliest time point, 30 min, and decreased thereafter (Fig. 5b) . Quantification of the PET data at the 2-h time point showed acceptable tumor-to-kidney (0.74) and tumor-to-liver (2.49) ratios. Biodistribution studies using dissected tissues gave somewhat different tumor-to-kidney and tumor-to-liver ratios of 0.48 and 4.8, respectively (Fig. 5c) .
However, FBEM- [Cys 40 ]-exendin showed even higher uptake in the INS-1 tumors based both on PET images (25.25±3.39% ID/g at 1 h) (Fig. 6a) and by biodistribution (Fig. 6b, c) . Tumor uptake peaked at 1 h, while kidney uptake had already begun to clear by that time. The biodistribution determined by counting of dissected tissues following a 2-h uptake period showed excellent tumor-to-kidney (7.4) and tumor-to-liver (39.9) ratios. Analysis of PET ROIs showed a tumor-to-kidney ratio of 4.94 and a tumor-to-liver ratio of 10. ]-exendin-4, the blocking dose resulted in a reduction in uptake in the intestine and increases in the kidneys, liver, and muscle.
Discussion
We have developed PET tracers for GLP-1R for potential imaging applications in neuroendocrine cancer, insulinoma, and diabetes. In addition, imaging applications may exist in cardiovascular disease because there is evidence that GLP-1R plays a role in cardiovascular function [24] . We wished to exploit the high resolution of PET by utilizing 18 F, which has the lowest positron range of the commonly used PET isotopes. In addition, the quantitative ability of PET is better than that of SPECT. The development and validation of novel radiopharmaceuticals for PET require optimization of radiochemical reactions, product purification and characterization, and confirmation of the compound's suitability for its biological purpose. ]-exendin-4 in mouse serum and human plasma. Supernatants from protein precipitation were analyzed by radioHPLC. The radiochemical peak at about 18 min represents parent compound
Mouse Serum
We previously synthesized and studied a bis-cyclic amide peptide (EM3106B) that contained a C-terminal cysteine for radiolabeling with [ 18 F]FBEM [18] . EM3106B was designed to resist metabolism through inclusion of two internal lactam loops [19] . We observed high uptake into the INS-1 tumor xenograft model and appropriate blocking was observed in GLP-1R-containing tissues. Compared with the synthetic preparation of the bis-cyclic amide EM3106B, the linear peptide structure of exendin-4 provides easy C-terminal or N-terminal cysteine modification using standard solid-phase peptide synthesis methods. These cysteine-modified exendin-4 analogs would be amenable to radiolabeling using our [ One of the advantages of maleimide conjugation with a mono cysteine-containing peptide is the mild reaction conditions employed. The radiochemical reaction proceeds well at room temperature in PBS. We added 0.1% sodium ascorbate to the incubation medium to slow the formation of disulfide dimers, a technique we had utilized previously in the synthesis of Affibody-based radiochemicals [25] . Even with the inclusion of sodium ascorbate in the incubation medium for the radiochemical reaction, oxidized FBEM-[Cys x ]-exendin-4 components were observed in varying amounts.
Previous studies on control of oxidative peptide modifications have indicated that methionine and tryptophan are the common sites of oxidation [26] . We made no attempt to determine the site of oxidation in our peptides. Concerns over the potential for methionine oxidation led to development of an exendin-4 analog named AC3174, which contains a leucine for methionine substitution [27] . Although the methionine oxidation was obviated, AC3174 has a shorter plasma half-life. The proteolytic stability of exendin-4 has previously been evaluated in human plasma [28] . The recovery of exendin-4 from human plasma using solid-phase techniques was about 50% and the half-life of the parent peptide was 9.57 h. The majority of the proteolytic degradation occurs in the N-terminal region. Since [ ]-exendin-4. Recovery of radioactivity from mouse serum following protein precipitation with acetonitrile was >80%, and the parent compound accounted for >88% of the extracted radioactivity. This percent recovery is much better than with the solid-phase method described above. Although the same high parent composition in extracted radioactivity was observed from human plasma, the extraction efficiency was only 72% and 68% at 30 and 60 min, respectively. This suggests that coprecipitation with plasma proteins may be a confounding factor for determining parent fraction in plasma.
For the purposes of biological validation of our new exendin-4 analogs, we selected the subcutaneous INS-1 tumor xenograft model. This is a convenient model, easily applied by a group with expertise in tumor xenograft models, to evaluate uptake of GLP-1R ligands. INS-1 expresses high levels of GLP-1R whereas MDA-MB-435, which we selected as a negative control, has very low (Fig. 4) . Tissue uptake was evaluated utilizing static PET imaging and the obligatory tissue dissection biodistribution following the imaging studies. The biodistribution studies using tissue dissection are useful for measuring uptake in smaller tissues and tissues with low uptake. Previous studies have demonstrated that modification of the N-terminal of exendin-4 decreases the biological activity as the N-terminal domain of exendin-4 is crucial for its agonist properties [4] . The N-terminal truncated exendin-(9-39)-amide is an antagonist at GLP-1R [29] ]-exendin-4 was 29%ID/g and 9.1%ID/g in INS-1 tumor and pancreas, respectively. Kidney uptake was high for both isomers, but because of the differences in tumor uptake, [ Blocking studies were undertaken with both compounds to identify tissues that have saturable uptake. Both compounds displayed >87 % (p<0.05) blocking in the INS-1 tumor, pancreas, and lung. In addition, the [Cys 40 ] isomer showed 52% (p<0.05) inhibition in the intestine and increases of more than 49% in the liver, kidneys, and muscle. We have no explanation for these increases. Previous results of blocking studies in INS-1 xenograft models have also indicated high blocking in INS-1 tumor, pancreas, stomach, and lung [12] . INS-1 tumor, pancreas and lung are known to contain GLP-1R. These results suggest that both of these compounds specifically bind GLP-1R.
The pancreas would be the major organ of interest for applications of GLP-1R imaging agents for the study of diabetes and the detection of insulinomas. Since insulinomas typically occur in the pancreas, liver and intestinal uptake is the major background source to be evaluated. 40 ] isomer was cleared from kidneys and liver resulting in a tumor-tokidney ratio of 4.94 and a tumor-to-liver ratio of 10.1 at 2 h after injection. Although, we were unable to visualize the pancreas with our small-animal PET scanner, biodistribution calculated based on tissue dissection indicated a pancreas-to-liver ratio of 12.2. Thus, if all other parameters remain constant, imaging the pancreas and insulinoma in larger animals and humans should be possible.
Conclusion
The combination of high uptake in INS-1 tumor and pancreas and the ability to block this uptake with a high mass dose suggests that [ 18 
